Neumora Therapeutics Inc (NMRA) COM USD0.0001

Sell:$0.68Buy:$0.68$0.04 (5.81%)

NASDAQ:1.00%
Market closed | Prices delayed by at least 15 minutes
Sell:$0.68
Buy:$0.68
Change:$0.04 (5.81%)
Market closed | Prices delayed by at least 15 minutes
Sell:$0.68
Buy:$0.68
Change:$0.04 (5.81%)
Market closed | Prices delayed by at least 15 minutes

Company Information

About this company

Neumora Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company's therapeutic pipeline consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its advanced product candidate, navacaprant (NMRA-140), is a novel once-daily oral kappa opioid receptor (KOR) antagonist that is being developed for the treatment of depressive disorder (MDD). Navacaprant is being investigated in the KOASTAL pivotal Phase 3 program, evaluating navacaprant monotherapy in patients with moderate to severe MDD. The Company's next advanced product candidate is NMRA-511, which is a highly selective, novel antagonist of the vasopressin 1a receptor (V1aR) being developed for the treatment of agitation associated with dementia due to Alzheimer's disease (AD).

Key people

Paul L. Berns
Chairman of the Board, Chief Executive Officer, Co-Founder
Joshua Pinto
President
Michael Lee Milligan
Chief Financial Officer, Principal Accounting Officer
Daljit Singh Aurora
Chief Operating Officer and Development
Jason G. Duncan
Chief Legal and Administrative Officer
Kristina M. Burow
Independent Director
Matthew K. Fust
Independent Director
Alaa A. Halawa
Independent Director
Maykin Ho
Independent Director
David Piacquad
Independent Director
Click to see more

Key facts

  • EPIC
    NMRA
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6409791000
  • Market cap
    $122.06m
  • Employees
    103
  • Shares in issue
    161.75m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.